Tunris Will we ever model PSC? Clin Gastroenterol Hepatol ; Histological and immunohistochemical study of the gallbladder lesion in primary sclerosing cholangitis. In each issue it also publishes one or two clinical cases that are of great interest to the readers, since they are usually exceptional cases that are difficult to diagnose or treat. European Association for the Study of the Liver. Oral nicotine in treatment of primary sclerosing cholangitis: Lancet, 2pp. Nat Genet ; Small-duct primary sclerosing cholangitis: Gallbladder disease in patients with primary sclerosing cholangitis.

Author:Jusar Vikora
Language:English (Spanish)
Published (Last):22 March 2012
PDF File Size:14.79 Mb
ePub File Size:16.80 Mb
Price:Free* [*Free Regsitration Required]

Hospital San Juan de Dios. Colangitis esclerosante primaria. The etiopathogenesis is unknown but it has seen multifactorial interaction in it; among the immunity disorders, intestinal toxic or infectious agents, ischemic deterioration of the bile ducts and possibly a variation in the hepatobiliary transporters. In its epidemiology it characterizes a higher frequency of appearance in men than in women, with an average age of 40 years.

Clinically it can be asymptomatic or with intrahepatic bile duct disease or associated with autoimmune hepatitis, in most cases it is associated with colitis and presents a chronic cholestatic process that finally leads to biliary cirrhosis. Biochemically it shows an analytic of cholestasis, but it does consider the diagnostic utility the use of endoscopic retrograde cholangiography or cholangioresonance as the first procedure that is equally informative and non-invasive, while liver biopsy is not essential for diagnosis.

Regarding the treatment of the disease, there is no curative drug, and despite the attempts with the use of ursodeoxycholic acid it has only been shown to be better in the biochemical alterations of cholestasis, accompanying a very controversial international panorama about its usefulness, leaving the liver transplantation as a last therapeutic resource with good survival expectations, although with a probability of recurrence of the disease in the transplanted liver..

La sobrevida en estos pacientes es en promedio de Acosta, J. Chemokine signaling via the CXCR2 receptor reinforces senescence. Cell, , Angulo, P. Magnetic resonance cholangiography in patients with biliary disease: Its role in primary sclerosing cholangitis.

Journal of Hepatology, 33, Primary sclerosing cholangitis. Hepatology, 30, Berstad, A. Diagnostic accuracy of magnetic resonance and endoscopic retrograde cholangiography in primary sclerosing cholangitis. Clinical Gastroenterology and Hepatology Journal, 4, Boonstra, K. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. Journal of Hepatology, 56, Brandsaeter, B. Liver Transplantation, 9, Chapman, R.

Diagnosis and management of primary sclerosing cholangitis. Hepatology, 51, Coppe, J. Senescence associated secretory phenotypes reveal cellnonautonomous functions of oncogenic RAS and the p53 tumor suppressor. PLOS Biology, 6, Eaton, J. Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management. Gastroenterology, Feldman, M. Elsevier, Fiorucci, S. A farnesoid X receptorsmall heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis.

Journal of Pharmacology and Experimental Therapeutics, , Fosby, B. Recurrence and rejection in liver transplantation for primary sclerosing cholangitis.

World Journal of Gastroenterology, 18, Hirschfield, G. Lancet, , Jussila, A. Malignancies in patients with inflammatory bowel disease: a nationwide register study in Finland. Scandinavian Journal Gastroenterology, 48, Konstantinos, N. Primary Sclerosing Cholangitis. The New England Journal of Medicine, , Kuilman, T. Oncogeneinduced senescence relayed by an interleukindependent inflammatory network.

Lindor, K. Ursodiol for primary sclerosing cholangitis. Highdose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology, 50, Liu, J. Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nature Genetics, 45, Mendes, F. Elevated serum IgG4 concentration in patients with primary sclerosing cholangitis. American Journal of Gastroenterology, , Molodecky, N. Incidence of primary sclerosing cholangitis: a systematic review and metaanalysis.

Hepatology, 53, Nakken, K. Scandinavian Journal Gastroenterology, 42, Cholangiocyte NRas protein mediates lipopolysaccharide induced interleukin 6 secretion and proliferation. The Journal of Biological Chemistry, , The dynamic biliary epithelia: molecules, pathways, and disease. Journal of Hepatology, 58, Stiehl, A. Primary sclerosing cholangitis: The role of endoscopic therapy. Seminars in Liver Disease, 26, Tabibian, J. Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis — a pilot study.

Cholangiocyte senescence by way of Nras activation is a characteristic of primary sclerosing cholangitis. Hepatology, 59, Tchkonia, T. Cellular senescence and the senescent secretory phenotype: therapeutic opportunities. The Journal of Clinical Investigation, , Trottier, J. Metabolomic profiling of 17 bile acids in serum from patients with primary biliary cirrhosis and primary sclerosing cholangitis: a pilot study. Digestive and Liver Disease Journal — Elsevier, 44, Vikas, K.



Colangite esclerosante primária



Resumen: Colangitis esclerosante primaria



Colangitis esclerosante primaria



Colangitis esclerosante primaria (CEP)


Related Articles